De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Ion Beam Applications Toekomstige groei

Future criteriumcontroles 4/6

Ion Beam Applications zal naar verwachting groeien in winst en omzet met respectievelijk 73.1% en 3.7% per jaar. De winst per aandeel zal naar verwachting groeien met 72.7% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 29.4% zijn.

Belangrijke informatie

73.1%

Groei van de winst

72.7%

Groei van de winst per aandeel

Medical Equipment winstgroei	18.8%
Inkomstengroei	3.7%
Toekomstig rendement op eigen vermogen	29.4%
Dekking van analisten	Low
Laatst bijgewerkt	24 Sep 2024

Recente toekomstige groei-updates

Recent updates

Is Now An Opportune Moment To Examine Ion Beam Applications SA (EBR:IBAB)?

Sep 19

It's Unlikely That The CEO Of Ion Beam Applications SA (EBR:IBAB) Will See A Huge Pay Rise This Year

Jun 06

Further Upside For Ion Beam Applications SA (EBR:IBAB) Shares Could Introduce Price Risks After 29% Bounce

Mar 25

Is Ion Beam Applications (EBR:IBAB) Using Too Much Debt?

Nov 07

Ion Beam Applications (EBR:IBAB) Has Some Way To Go To Become A Multi-Bagger

Oct 05

Ion Beam Applications (EBR:IBAB) Is Investing Its Capital With Increasing Efficiency

Jan 31

Is Ion Beam Applications (EBR:IBAB) A Risky Investment?

Sep 28

Here's Why Shareholders May Want To Be Cautious With Increasing Ion Beam Applications SA's (EBR:IBAB) CEO Pay Packet

Jun 01

Ion Beam Applications' (EBR:IBAB) Returns On Capital Are Heading Higher

May 29

Does Ion Beam Applications SA (EBR:IBAB) Have A Place In Your Dividend Stock Portfolio?

Apr 20

Is Ion Beam Applications (EBR:IBAB) A Risky Investment?

Mar 30

Should You Use Ion Beam Applications' (EBR:IBAB) Statutory Earnings To Analyse It?

Feb 10

What Type Of Shareholders Make Up Ion Beam Applications SA's (EBR:IBAB) Share Registry?

Jan 06

Does This Valuation Of Ion Beam Applications SA (EBR:IBAB) Imply Investors Are Overpaying?

Dec 10

Ion Beam Applications' (EBR:IBAB) Shareholders Are Down 64% On Their Shares

Nov 17

Ion Beam Applications SA (EBR:IBAB) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?

Aug 20

Estimating The Intrinsic Value Of Ion Beam Applications SA (EBR:IBAB)

Jul 21

Winst- en omzetgroeiprognoses

ENXTBR:IBAB - Toekomstschattingen van analisten en financiële gegevens uit het verleden (EUR Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	612	47	74	75	3
12/31/2025	570	32	-18	10	3
12/31/2024	478	7	-86	-62	3
6/30/2024	466	8	-37	-27	N/A
3/31/2024	447	-1	-34	-23	N/A
12/31/2023	429	-9	-32	-20	N/A
9/30/2023	400	-14	-45	-33	N/A
6/30/2023	371	-19	-59	-47	N/A
3/31/2023	366	-7	-22	-13	N/A
12/31/2022	361	6	14	22	N/A
9/30/2022	349	5	54	60	N/A
6/30/2022	336	4	93	98	N/A
3/31/2022	324	4	87	93	N/A
12/31/2021	313	4	82	87	N/A
9/30/2021	326	23	83	87	N/A
6/30/2021	339	42	83	87	N/A
3/31/2021	326	37	90	94	N/A
12/31/2020	312	32	96	100	N/A
9/30/2020	288	16	N/A	N/A	N/A
6/30/2020	264	1	69	73	N/A
3/31/2020	273	4	56	61	N/A
12/31/2019	283	8	44	49	N/A
9/30/2019	325	5	N/A	N/A	N/A
6/30/2019	295	-2	-9	11	N/A
3/31/2019	276	-3	-23	-4	N/A
1/1/2019	257	-4	-37	-19	N/A
9/30/2018	229	-25	-53	-40	N/A
6/30/2018	175	-45	-68	-61	N/A
3/31/2018	206	-43	N/A	-53	N/A
12/31/2017	236	-42	N/A	-45	N/A
9/30/2017	311	-14	N/A	-30	N/A
6/30/2017	335	12	N/A	-15	N/A
3/31/2017	332	18	N/A	-16	N/A
12/31/2016	329	25	N/A	-17	N/A
9/30/2016	312	40	N/A	-1	N/A
6/30/2016	294	55	N/A	15	N/A
3/31/2016	282	58	N/A	30	N/A
1/1/2016	270	61	N/A	45	N/A
10/1/2015	257	46	N/A	31	N/A
6/30/2015	243	31	N/A	17	N/A
3/31/2015	232	26	N/A	16	N/A
12/31/2014	221	21	N/A	15	N/A
9/30/2014	217	9	N/A	31	N/A
6/30/2014	213	-2	N/A	47	N/A
3/31/2014	213	-3	N/A	27	N/A
12/31/2013	213	-4	N/A	7	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei IBAB ( 73.1% per jaar) ligt boven de spaarquote ( 1.3% ).

Winst versus markt: De winst van IBAB ( 73.1% per jaar) zal naar verwachting sneller groeien dan de Belgian markt ( 18.8% per jaar).

Hoge groeiwinsten: De winst van IBAB zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van IBAB ( 3.7% per jaar) zal naar verwachting langzamer groeien dan de markt Belgian ( 7.5% per jaar).

Hoge groei-inkomsten: De omzet van IBAB ( 3.7% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen IBAB zal naar verwachting over 3 jaar hoog zijn ( 29.4 %)

Ion Beam Applications Toekomstige groei

Future criteriumcontroles 4/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus EPS estimates fall from profit to €0.16 loss

Price target increased by 12% to €17.50

Consensus EPS estimates fall by 20%

Price target decreased by 18% to €18.00

Price target increased by 26% to €22.30

Price target increased to €19.25

Recent updates

Is Now An Opportune Moment To Examine Ion Beam Applications SA (EBR:IBAB)?

Investor sentiment improves as stock rises 24%

Consensus EPS estimates fall from profit to €0.16 loss

First half 2024 earnings released

Ion Beam Applications SA to Report Q1, 2025 Results on May 22, 2025

Dividend of €0.12 announced

It's Unlikely That The CEO Of Ion Beam Applications SA (EBR:IBAB) Will See A Huge Pay Rise This Year

Price target increased by 12% to €17.50

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Further Upside For Ion Beam Applications SA (EBR:IBAB) Shares Could Introduce Price Risks After 29% Bounce

Full year 2023 earnings released

Ion Beam Applications SA to Report First Half, 2024 Results on Aug 29, 2024

Ion Beam Applications S.A., CMI Inc. and Life Molecular Imaging Announce Japanese Approval for the Reimbursement of Amyloid-Pet Diagnostic Neuraceq in Alzheimer's Disease

Consensus EPS estimates fall by 20%

Ion Beam Applications SA, Annual General Meeting, Jun 12, 2024

Is Ion Beam Applications (EBR:IBAB) Using Too Much Debt?

New minor risk - Share price stability

Ion Beam Applications S.A Plans Total System Restoration on its First-Ever Proton Therapy Installation

Price target decreased by 18% to €18.00

Insufficient new directors

Price target increased by 26% to €22.30

Full year 2022 earnings released

Ion Beam Applications SA to Report Q1, 2023 Results on May 18, 2023

Price target increased to €19.25

Ion Beam Applications (EBR:IBAB) Has Some Way To Go To Become A Multi-Bagger

First half 2022 earnings released: €0.059 loss per share (vs €0.066 loss in 1H 2021)

Ion Beam Applications SA Continues to Shape the Future of Proton Therapy At Estro 2022 Annual Congress

Ion Beam Applications SA (ENXTBR:IBAB) acquired Modus Medical Devices Inc.

Full year 2021 earnings: EPS exceeds analyst expectations

Price target increased to €17.75

Investor sentiment improved over the past week

Ion Beam Applications (EBR:IBAB) Is Investing Its Capital With Increasing Efficiency

IBA Launches Compact Low-Energy Cyclotron, Cyclone® KEY

First half 2021 earnings released: €0.066 loss per share (vs €0.41 loss in 1H 2020)

First half 2021 earnings released: €0.066 loss per share (vs €0.41 loss in 1H 2020)

First half 2021 earnings released: €0.066 loss per share (vs €0.41 loss in 1H 2020)

Is Ion Beam Applications (EBR:IBAB) A Risky Investment?

First half 2021 earnings released

Ion Beam Applications S.A. Announces Launch of a Large-Scale, Multi-Institutional, Randomized Controlled Clinical Trial

Price target increased to €15.00

Here's Why Shareholders May Want To Be Cautious With Increasing Ion Beam Applications SA's (EBR:IBAB) CEO Pay Packet

Ion Beam Applications' (EBR:IBAB) Returns On Capital Are Heading Higher

Does Ion Beam Applications SA (EBR:IBAB) Have A Place In Your Dividend Stock Portfolio?

Is Ion Beam Applications (EBR:IBAB) A Risky Investment?

Full year 2020 earnings released

IBA (Ion Beam Applications S.A. and NorthStar Medical Radioisotopes Expand Collaboration to Enable Global Availability of Diagnostic Radioisotope Technetium-99m (Tc-99m)

Ion Beam Applications SA Receives Down Payment from National Cancer Center Korea for A Second Proteus® System

Should You Use Ion Beam Applications' (EBR:IBAB) Statutory Earnings To Analyse It?

Price target raised to €12.60

Ion Beam Applications SA to Report Q3, 2021 Results on Nov 18, 2021

New 90-day high: €13.46

What Type Of Shareholders Make Up Ion Beam Applications SA's (EBR:IBAB) Share Registry?

Does This Valuation Of Ion Beam Applications SA (EBR:IBAB) Imply Investors Are Overpaying?

Ion Beam Applications' (EBR:IBAB) Shareholders Are Down 64% On Their Shares

New 90-day high: €11.96

New 90-day high: €11.68

Ion Beam Applications SA Signs Contract for the First End-To-End Rhodotron® Duo Solution for Multi-Purpose Irradiation in Taiwan

Ion Beam Applications SA Announces First Payment of EUR 20 Million Received for Strategic Licensing Deal in China

New 90-day high: €10.60

Ion Beam Applications SA to Report Fiscal Year 2020 Results on Mar 25, 2021

New 90-day low - €7.14

Ion Beam Applications SA (EBR:IBAB) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?

New 90-day low - €7.30

Estimating The Intrinsic Value Of Ion Beam Applications SA (EBR:IBAB)

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven